{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T11:20:49Z","timestamp":1783077649278,"version":"3.54.6"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006310","name":"Swedish Medical Research Council","doi-asserted-by":"crossref","award":["2021-01755"],"award-info":[{"award-number":["2021-01755"]}],"id":[{"id":"10.13039\/501100006310","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["2023-01988"],"award-info":[{"award-number":["2023-01988"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Swedish Childhood Cancer Fund","award":["PR2022-0066"],"award-info":[{"award-number":["PR2022-0066"]}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Combination therapy integrating bispecific antibody (BsAb) and oncolytic viruses (OVs) to enhance antitumor immune response offers a promising therapeutic approach in comparison with OV treatment alone. This study aims to strengthen and characterize NK cell-mediated antitumor responses using modified oncolytic viruses, i.e., ONCOS-102 and ONCOS-204 genetically engineered to express Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and the ligand of inducible T-cell co-stimulator (ICOSL), respectively, in combination with a BsAb targeting CD16 and the epidermal growth factor receptor (EGFR). Changes in phenotype, degranulation, cytokine production, and cytotoxicity of NK cells induced by combined treatment were compared with those induced by\u00a0individual treatment strategies against non-small cell lung cancer, malignant melanoma, and ovarian cancer. Using flow cytometry and colorimetry-based cytotoxic assays, our results showed that EGFRxCD16 BsAb was the main variable in driving NK cells toward an activated phenotype and enhanced NK function; while the OVs alone did not demonstrate drastic impact on NK cells. Interestingly, tumor preconditioning with OVs in combination with EGFRxCD16 BsAb showed the most potent NK cytotoxicity in comparison with EGFRxCD16 BsAb alone and appeared to synergize best against ovarian and EGFRmut lung tumor cell lines. Despite differences between tumor types, our data suggest a favorable interplay between OVs, especially ONCOS-102, and EGFRxCD16 BsAb \u00a0in sensitizing NK cell antitumor response in vitro. These results warrant further in vivo exploration and clinical translation of this promising combination of therapeutic modalities.<\/jats:p>","DOI":"10.1007\/s00262-026-04470-4","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:55:04Z","timestamp":1783058104000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["EGFRxCD16 bispecific antibodies orchestrate superior NK cell-mediated lysis of ovarian cancer and NSCLC cell lines in combination with oncolytic viruses"],"prefix":"10.1007","volume":"75","author":[{"given":"Sarah","family":"Gahbauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Poiret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"4470_CR1","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/sj.mt.6300108","volume":"15","author":"E Kelly","year":"2007","unstructured":"Kelly E, Russell SJ (2007) History of oncolytic viruses: genesis to genetic engineering. Mol Ther 15:651\u2013659. https:\/\/doi.org\/10.1038\/sj.mt.6300108","journal-title":"Mol Ther"},{"key":"4470_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","volume":"7","author":"RHI Andtbacka","year":"2019","unstructured":"Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G, \u04e6hrling K, Kaufman HL (2019) Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer 7:145. https:\/\/doi.org\/10.1186\/s40425-019-0623-z","journal-title":"J Immunother Cancer"},{"key":"4470_CR3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s40259-022-00553-7","volume":"36","author":"JE Frampton","year":"2022","unstructured":"Frampton JE (2022) Teserpaturev\/G47Delta: First Approval. BioDrugs 36:667\u2013672. https:\/\/doi.org\/10.1007\/s40259-022-00553-7","journal-title":"BioDrugs"},{"key":"4470_CR4","doi-asserted-by":"publisher","unstructured":"Vazaios K, van Berkum RE, Calkoen FG, van der Lugt J, Hulleman E (2024) OV Modulators of the Paediatric Brain TIME: Current Status, Combination Strategies, Limitations and Future Directions. Int J Mol Sci. 25. https:\/\/doi.org\/10.3390\/ijms25095007","DOI":"10.3390\/ijms25095007"},{"key":"4470_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","volume":"9","author":"R Ma","year":"2023","unstructured":"Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J (2023) The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer 9:122\u2013139. https:\/\/doi.org\/10.1016\/j.trecan.2022.10.003","journal-title":"Trends Cancer"},{"key":"4470_CR6","doi-asserted-by":"publisher","first-page":"1591875","DOI":"10.1080\/2162402X.2019.1591875","volume":"8","author":"PK Bommareddy","year":"2019","unstructured":"Bommareddy PK, Zloza A, Rabkin SD, Kaufman HL (2019) Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma. Oncoimmunology 8:1591875. https:\/\/doi.org\/10.1080\/2162402X.2019.1591875","journal-title":"Oncoimmunology"},{"key":"4470_CR7","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1002\/1878-0261.12851","volume":"14","author":"A Ahmed","year":"2020","unstructured":"Ahmed A, Tait SWG (2020) Targeting immunogenic cell death in cancer. Mol Oncol 14:2994\u20133006. https:\/\/doi.org\/10.1002\/1878-0261.12851","journal-title":"Mol Oncol"},{"key":"4470_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/cgt.2016.8","volume":"23","author":"A Takasu","year":"2016","unstructured":"Takasu A, Masui A, Hamada M, Imai T, Iwai S, Yura Y (2016) Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells. Cancer Gene Ther 23:107\u2013113. https:\/\/doi.org\/10.1038\/cgt.2016.8","journal-title":"Cancer Gene Ther"},{"key":"4470_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.omto.2018.10.005","volume":"11","author":"R Havunen","year":"2018","unstructured":"Havunen R, Santos JM, Sorsa S et al (2018) Abscopal effect in non-injected tumors achieved with cytokine-armed oncolytic adenovirus. Mol Ther Oncolytics 11:109\u2013121. https:\/\/doi.org\/10.1016\/j.omto.2018.10.005","journal-title":"Mol Ther Oncolytics"},{"key":"4470_CR10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1126\/science.285.5428.727","volume":"285","author":"S Bauer","year":"1999","unstructured":"Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727\u2013729. https:\/\/doi.org\/10.1126\/science.285.5428.727","journal-title":"Science"},{"key":"4470_CR11","first-page":"6178","volume":"62","author":"D Pende","year":"2002","unstructured":"Pende D, Rivera P, Marcenaro S et al (2002) Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 62:6178\u20136186","journal-title":"Cancer Res"},{"key":"4470_CR12","doi-asserted-by":"publisher","first-page":"1207276","DOI":"10.3389\/fimmu.2023.1207276","volume":"14","author":"M Zhang","year":"2023","unstructured":"Zhang M, Lam KP, Xu S (2023) Natural killer cell engagers (NKCEs): a new frontier in cancer immunotherapy. Front Immunol 14:1207276. https:\/\/doi.org\/10.3389\/fimmu.2023.1207276","journal-title":"Front Immunol"},{"key":"4470_CR13","first-page":"218","volume":"12","author":"G Trinchieri","year":"1993","unstructured":"Trinchieri G, Valiante N (1993) Receptors for the Fc fragment of IgG on natural killer cells. Nat Immun 12:218\u2013234","journal-title":"Nat Immun"},{"key":"4470_CR14","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrm1962","volume":"7","author":"A Citri","year":"2006","unstructured":"Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505\u2013516. https:\/\/doi.org\/10.1038\/nrm1962","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4470_CR15","doi-asserted-by":"publisher","first-page":"826","DOI":"10.37349\/etat.2024.00251","volume":"5","author":"K Akao","year":"2024","unstructured":"Akao K, Oya Y, Sato T, Ikeda A, Horiguchi T, Goto Y, Hashimoto N, Kondo M, Imaizumi K (2024) It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC. Explor Target Antitumor Ther 5:826\u2013840. https:\/\/doi.org\/10.37349\/etat.2024.00251","journal-title":"Explor Target Antitumor Ther"},{"key":"4470_CR16","doi-asserted-by":"publisher","unstructured":"Banisadr A, Eick M, Beri P, Parisian AD, Yeoman B, Placone JK, Engler AJ, Furnari F (2020) EGFRvIII uses intrinsic and extrinsic mechanisms to reduce glioma adhesion and increase migration. J Cell Sci. https:\/\/doi.org\/10.1242\/jcs.247189","DOI":"10.1242\/jcs.247189"},{"key":"4470_CR17","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1200\/JCO.21.01691","volume":"39","author":"S Devarakonda","year":"2021","unstructured":"Devarakonda S, Li Y, Martins Rodrigues F et al (2021) Genomic profiling of lung adenocarcinoma in never-smokers. J Clin Oncol 39:3747\u20133758. https:\/\/doi.org\/10.1200\/JCO.21.01691","journal-title":"J Clin Oncol"},{"key":"4470_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100819","volume":"3","author":"AR Soltis","year":"2022","unstructured":"Soltis AR, Bateman NW, Liu J et al (2022) Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways. Cell Rep Med 3:100819. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100819","journal-title":"Cell Rep Med"},{"key":"4470_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba8564","volume":"6","author":"KM Au","year":"2020","unstructured":"Au KM, Park SI, Wang AZ (2020) Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy. Sci Adv 6:eaba8564. https:\/\/doi.org\/10.1126\/sciadv.aba8564","journal-title":"Sci Adv"},{"key":"4470_CR20","doi-asserted-by":"publisher","first-page":"27764","DOI":"10.18632\/oncotarget.8526","volume":"7","author":"X Chen","year":"2016","unstructured":"Chen X, Han J, Chu J et al (2016) A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget 7:27764\u201327777. https:\/\/doi.org\/10.18632\/oncotarget.8526","journal-title":"Oncotarget"},{"key":"4470_CR21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41419-023-05624-3","volume":"14","author":"A Floerchinger","year":"2023","unstructured":"Floerchinger A, Klein JE, Finkbeiner MSC et al (2023) A vector-encoded bispecific killer engager to harness virus-activated NK cells as anti-tumor effectors. Cell Death Dis 14:104. https:\/\/doi.org\/10.1038\/s41419-023-05624-3","journal-title":"Cell Death Dis"},{"key":"4470_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00262-023-03611-3","volume":"73","author":"M Costa-Garcia","year":"2024","unstructured":"Costa-Garcia M, Rojas JJ, Ramos MD, Barlabe P, Calvo P, Navas J, Alemany R, Moreno R (2024) Oncolytic adenovirus coding for shedding-resistant MICA enhances immune responses against tumors. Cancer Immunol Immunother 73:5. https:\/\/doi.org\/10.1007\/s00262-023-03611-3","journal-title":"Cancer Immunol Immunother"},{"key":"4470_CR23","doi-asserted-by":"publisher","unstructured":"Ravirala D, Mistretta B, Gunaratne PH, Pei G, Zhao Z, Zhang X (2021) Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy. J Immunother Cancer. 9. https:\/\/doi.org\/10.1136\/jitc-2021-002454","DOI":"10.1136\/jitc-2021-002454"},{"key":"4470_CR24","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12967-024-05049-2","volume":"22","author":"N Saffarzadeh","year":"2024","unstructured":"Saffarzadeh N, Foord E, O\u2019Leary E, Mahmoun R, Birkballe Hansen T, Levitsky V, Poiret T, Uhlin M (2024) Inducing expression of ICOS-L by oncolytic adenovirus to enhance tumor-specific bi-specific antibody efficacy. J Transl Med 22:250. https:\/\/doi.org\/10.1186\/s12967-024-05049-2","journal-title":"J Transl Med"},{"key":"4470_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219449","volume":"14","author":"M Montes-Casado","year":"2019","unstructured":"Montes-Casado M, Ojeda G, Aragoneses-Fenoll L, Lopez D, de Andres B, Gaspar ML, Dianzani U, Rojo JM, Portoles P (2019) ICOS deficiency hampers the homeostasis, development and function of NK cells. PLoS ONE 14:e0219449. https:\/\/doi.org\/10.1371\/journal.pone.0219449","journal-title":"PLoS ONE"},{"key":"4470_CR26","doi-asserted-by":"publisher","unstructured":"Rojas-Diaz JM, Solorzano-Ibarra F, Garcia-Barrientos NT et al. (2024) Uncovering the expression pattern of the costimulatory receptors ICOS, 4\u20131BB, and OX-40 in exhausted peripheral and tumor-infiltrating natural killer cells from patients with cervical cancer. Int J Mol Sci, 25. https:\/\/doi.org\/10.3390\/ijms25168775","DOI":"10.3390\/ijms25168775"},{"key":"4470_CR27","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1182\/blood-2013-10-533398","volume":"123","author":"MK Gleason","year":"2014","unstructured":"Gleason MK, Ross JA, Warlick ED et al (2014) CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood 123:3016\u20133026. https:\/\/doi.org\/10.1182\/blood-2013-10-533398","journal-title":"Blood"},{"key":"4470_CR28","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1038\/mt.2016.88","volume":"24","author":"JU Schmohl","year":"2016","unstructured":"Schmohl JU, Felices M, Taras E, Miller JS, Vallera DA (2016) Enhanced ADCC and NK cell activation of an anticarcinoma bispecific antibody by genetic insertion of a modified IL-15 cross-linker. Mol Ther 24:1312\u20131322. https:\/\/doi.org\/10.1038\/mt.2016.88","journal-title":"Mol Ther"},{"key":"4470_CR29","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1182\/bloodadvances.2018018176","volume":"2","author":"HD Yun","year":"2018","unstructured":"Yun HD, Felices M, Vallera DA, Hinderlie P, Cooley S, Arock M, Gotlib J, Ustun C, Miller JS (2018) Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. Blood Adv 2:1580\u20131584. https:\/\/doi.org\/10.1182\/bloodadvances.2018018176","journal-title":"Blood Adv"},{"key":"4470_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1600-065X.2006.00457.x","volume":"214","author":"YT Bryceson","year":"2006","unstructured":"Bryceson YT, March ME, Ljunggren HG, Long EO (2006) Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 214:73\u201391. https:\/\/doi.org\/10.1111\/j.1600-065X.2006.00457.x","journal-title":"Immunol Rev"},{"key":"4470_CR31","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1182\/blood-2012-04-425397","volume":"121","author":"R Romee","year":"2013","unstructured":"Romee R, Foley B, Lenvik T et al (2013) NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 121:3599\u20133608. https:\/\/doi.org\/10.1182\/blood-2012-04-425397","journal-title":"Blood"},{"key":"4470_CR32","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1083\/jcb.201712085","volume":"217","author":"K Srpan","year":"2018","unstructured":"Srpan K, Ambrose A, Karampatzakis A, Saeed M, Cartwright ANR, Guldevall K, De Matos G, Onfelt B, Davis DM (2018) Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells. J Cell Biol 217:3267\u20133283. https:\/\/doi.org\/10.1083\/jcb.201712085","journal-title":"J Cell Biol"},{"key":"4470_CR33","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1182\/blood.v99.7.2490","volume":"99","author":"S Deaglio","year":"2002","unstructured":"Deaglio S, Zubiaur M, Gregorini A, Bottarel F, Ausiello CM, Dianzani U, Sancho J, Malavasi F (2002) Human CD38 and CD16 are functionally dependent and physically associated in natural killer cells. Blood 99:2490\u20132498. https:\/\/doi.org\/10.1182\/blood.v99.7.2490","journal-title":"Blood"},{"key":"4470_CR34","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/intimm\/13.4.397","volume":"13","author":"R Mallone","year":"2001","unstructured":"Mallone R, Funaro A, Zubiaur M, Baj G, Ausiello CM, Tacchetti C, Sancho J, Grossi C, Malavasi F (2001) Signaling through CD38 induces NK cell activation. Int Immunol 13:397\u2013409. https:\/\/doi.org\/10.1093\/intimm\/13.4.397","journal-title":"Int Immunol"},{"key":"4470_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202250198","volume":"53","author":"ND Milito","year":"2023","unstructured":"Milito ND, Zingoni A, Stabile H et al (2023) NKG2D engagement on human NK cells leads to DNAM-1 hypo-responsiveness through different converging mechanisms. Eur J Immunol 53:e2250198. https:\/\/doi.org\/10.1002\/eji.202250198","journal-title":"Eur J Immunol"},{"key":"4470_CR36","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1172\/JCI11517","volume":"107","author":"P Fraticelli","year":"2001","unstructured":"Fraticelli P, Sironi M, Bianchi G et al (2001) Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 107:1173\u20131181. https:\/\/doi.org\/10.1172\/JCI11517","journal-title":"J Clin Invest"},{"key":"4470_CR37","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1365-2567.2011.03409.x","volume":"133","author":"I Hamann","year":"2011","unstructured":"Hamann I, Unterwalder N, Cardona AE, Meisel C, Zipp F, Ransohoff RM, Infante-Duarte C (2011) Analyses of phenotypic and functional characteristics of CX3CR1-expressing natural killer cells. Immunology 133:62\u201373. https:\/\/doi.org\/10.1111\/j.1365-2567.2011.03409.x","journal-title":"Immunology"},{"key":"4470_CR38","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","volume":"112","author":"MA Caligiuri","year":"2008","unstructured":"Caligiuri MA (2008) Human natural killer cells. Blood 112:461\u2013469. https:\/\/doi.org\/10.1182\/blood-2007-09-077438","journal-title":"Blood"},{"key":"4470_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010205","author":"ML Guevara Lopez","year":"2025","unstructured":"Guevara Lopez ML, Gebo A, Parodi M et al (2025) CD56(bright) cytokine-induced memory-like NK cells and NK-cell engagers synergize against non-small cell lung cancer cancer-stem cells. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2024-010205","journal-title":"J Immunother Cancer"},{"key":"4470_CR40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1073\/pnas.87.1.93","volume":"87","author":"SA Cannistra","year":"1990","unstructured":"Cannistra SA, Groshek P, Garlick R, Miller J, Griffin JD (1990) Regulation of surface expression of the granulocyte\/macrophage colony-stimulating factor receptor in normal human myeloid cells. Proc Natl Acad Sci U S A 87:93\u201397. https:\/\/doi.org\/10.1073\/pnas.87.1.93","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4470_CR41","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1182\/blood-2004-01-0380","volume":"104","author":"C Borg","year":"2004","unstructured":"Borg C, Jalil A, Laderach D et al (2004) NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood 104:3267\u20133275. https:\/\/doi.org\/10.1182\/blood-2004-01-0380","journal-title":"Blood"},{"key":"4470_CR42","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.4049\/jimmunol.1601477","volume":"199","author":"L Gorvel","year":"2017","unstructured":"Gorvel L, Korenfeld D, Tung T, Klechevsky E (2017) Dendritic cell-derived IL-32alpha: a novel inhibitory cytokine of NK cell function. J Immunol 199:1290\u20131300. https:\/\/doi.org\/10.4049\/jimmunol.1601477","journal-title":"J Immunol"},{"key":"4470_CR43","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41586-023-05912-0","volume":"616","author":"S Sen Santara","year":"2023","unstructured":"Sen Santara S, Lee DJ, Crespo A et al (2023) The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells. Nature 616:348\u2013356. https:\/\/doi.org\/10.1038\/s41586-023-05912-0","journal-title":"Nature"},{"key":"4470_CR44","doi-asserted-by":"publisher","first-page":"375","DOI":"10.21873\/cgp.20389","volume":"20","author":"H Shigeto","year":"2023","unstructured":"Shigeto H, Miyata H, Ashizawa T et al (2023) Localization of EGFR mutations in non-small-cell lung cancer tissues using mutation-specific PNA-DNA probes. Cancer Genomics Proteomics 20:375\u2013382. https:\/\/doi.org\/10.21873\/cgp.20389","journal-title":"Cancer Genomics Proteomics"},{"key":"4470_CR45","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/s41417-025-00962-0","volume":"32","author":"H Cao","year":"2025","unstructured":"Cao H, Ye J, Li X et al (2025) A novel GM-CSF-encoding oncolytic adenovirus induces profound autophagy and promotes viral replication to enhance anti-tumor efficacy. Cancer Gene Ther 32:1276\u20131291. https:\/\/doi.org\/10.1038\/s41417-025-00962-0","journal-title":"Cancer Gene Ther"},{"key":"4470_CR46","first-page":"1936","volume":"6","author":"CJ Bruns","year":"2000","unstructured":"Bruns CJ, Harbison MT, Davis DW et al (2000) Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 6:1936\u20131948","journal-title":"Clin Cancer Res"},{"key":"4470_CR47","first-page":"1935","volume":"59","author":"SM Huang","year":"1999","unstructured":"Huang SM, Bock JM, Harari PM (1999) Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59:1935\u20131940","journal-title":"Cancer Res"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04470-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04470-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04470-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:34:42Z","timestamp":1783074882000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04470-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":47,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["4470"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04470-4","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant conflict of interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"178"}}